Secukinumab provides sustained low rates of radiographic progression in psoriatic arthritis: 52-week results from a phase 3 study, FUTURE 5

Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial

(2015) Iain B McInnes et al.   LANCET

Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis

(2015) Philip J. Mease et al.   NEW ENGLAND JOURNAL OF MEDICINE

Focal bone involvement in inflammatory arthritis: the role of IL17

(2015) Maurizio Rossini et al.   RHEUMATOLOGY INTERNATIONAL

Clinical efficacy, radiographic and safety findings through 5 years of subcutaneous golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of a randomised, placebo-controlled trial (the GO-REVEAL study)

(2014) Arthur Kavanaugh et al.   ANNALS OF THE RHEUMATIC DISEASES

Managing Patients with Psoriatic Disease: The Diagnosis and Pharmacologic Treatment of Psoriatic Arthritis in Patients with Psoriasis

(2014) Philip J. Mease et al.   DRUGS

Interleukin-17+CD8+ T Cells Are Enriched in the Joints of Patients With Psoriatic Arthritis and Correlate With Disease Activity and Joint Damage Progression

(2014) Bina Menon et al.   Arthritis & Rheumatology

Effect of different imputation approaches on the evaluation of radiographic progression in patients with psoriatic arthritis: results of the RAPID-PsA 24-week phase III double-blind randomised placebo-controlled study of certolizumab pegol

(2013) D van der Heijde et al.   ANNALS OF THE RHEUMATIC DISEASES

World Medical Association Declaration of Helsinki

(2013)   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Psoriatic Arthritis

(2012) M. S. Day et al.   JOURNAL OF THE AMERICAN ACADEMY OF ORTHOPAEDIC SURGEONS

Patients with psoriatic arthritis have worse quality of life than those with psoriasis alone

(2011) C. F. Rosen et al.   RHEUMATOLOGY

Inflammation in an individual joint predicts damage to that joint in psoriatic arthritis

(2010) L. Cresswell et al.   ANNALS OF THE RHEUMATIC DISEASES

Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate

(2008) G Wells et al.   ANNALS OF THE RHEUMATIC DISEASES

Measuring clinical enthesitis in psoriatic arthritis: Assessment of existing measures and development of an instrument specific to psoriatic arthritis

(2008) Paul J. Healy et al.   ARTHRITIS AND RHEUMATISM

Guidelines of care for the management of psoriasis and psoriatic arthritis

(2008) Alice Gottlieb et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY